Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.

Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T, Xu L.

Mol Cancer Ther. 2008 Jul;7(7):2192-202. doi: 10.1158/1535-7163.MCT-08-0333.

2.

R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.

Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S.

Exp Hematol. 2008 May;36(5):568-76. doi: 10.1016/j.exphem.2008.01.003. Epub 2008 Mar 17.

3.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

5.

Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells.

Ko CH, Shen SC, Yang LY, Lin CW, Chen YC.

Int J Cancer. 2007 Oct 15;121(8):1670-9.

6.

(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.

Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ.

Neoplasia. 2006 Mar;8(3):163-72.

7.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
8.

Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.

Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A.

Mol Cancer Ther. 2005 Jan;4(1):13-21.

9.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

N Engl J Med. 2004 Oct 7;351(15):1513-20.

10.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators.

N Engl J Med. 2004 Oct 7;351(15):1502-12.

11.
12.

Gossypol, a pigment of cottonseed.

ADAMS R, GEISSMAN TA, EDWARDS JD.

Chem Rev. 1960 Dec;60:555-74. No abstract available.

PMID:
13681414
13.

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.

Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C.

Breast Cancer Res Treat. 2001 Apr;66(3):239-48.

PMID:
11510695
14.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
15.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ.

J Clin Oncol. 1999 Aug;17(8):2506-13.

PMID:
10561316
16.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al.

J Clin Oncol. 1999 Nov;17(11):3461-7. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702. J Clin Oncol 2000 Jul;18(13):2644. J Clin Oncol. 2007 Mar 20;25(9):1154.

PMID:
10550143
17.

Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest.

Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, Pietenpol JA.

J Biol Chem. 1998 Nov 13;273(46):30777-84.

18.

Bcl2 is the guardian of microtubule integrity.

Haldar S, Basu A, Croce CM.

Cancer Res. 1997 Jan 15;57(2):229-33.

19.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC.

J Clin Oncol. 1996 Jun;14(6):1756-64.

PMID:
8656243
20.

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

Haldar S, Chintapalli J, Croce CM.

Cancer Res. 1996 Mar 15;56(6):1253-5.

Supplemental Content

Support Center